Enter multiple symbols separated by commas

Momenta Pharmaceuticals Inc


  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote "all necessary resources" to its $40 billion- plus bid for rival Mylan Inc..

  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries, which is seeking to acquire rival Mylan Inc for over $40 billion, raised its full-year earnings outlook after posting a bigger-than-expected increase in first-quarter profit.

  • The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...

  • April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET
    'Rare Good News' on Health Care Retirement Savings: Study

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Stocks to Watch: BUD, STZ, WMT & More Monday, 25 Jun 2012 | 12:47 PM ET

    Take a look at some of Monday's midday movers:

  • What's Shaking: Monday's Early Movers Monday, 30 Jan 2012 | 8:28 AM ET

    Take a look at some of Monday morning's early movers:

  • Mad Mail: MedAssets, Momenta Pharmaceuticals and More Saturday, 26 Mar 2011 | 12:45 PM ET

    When someone calls about a stock Cramer doesn't know, he does his homework and follows up.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Small-cap companies with an almost 400% return Thursday, 28 Aug 2008 | 9:53 AM ET

    So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500.  While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown. 

  • Winners & Losers: Retailers Rule Tuesday, 6 Nov 2007 | 5:58 PM ET

    Rising oil prices have not stopped consumers from going to the mall.  Retailer Guess is enjoying a 15% surge in their stock price. The clothing company reported better than expected revenue.